U
uniQure N.V. (QURE)
NMS – Real Time Price. Currency in USD
29.00
-0.10 (-0.34%)
Market open: May 13, 2026, 9:30 AM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NMS – Real Time Price. Currency in USD
29.00
-0.10 (-0.34%)
Market open: May 13, 2026, 9:30 AM EDT
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
| Name | Position |
|---|---|
| Dr. Amin Abujoub Ph.D. | Chief Technical Operations Officer |
| Dr. Jeannette Potts J.D., Ph.D. | Chief Legal & Compliance Officer and Corporate Secretary |
| Dr. Tamara Tugal Ph.D., MBA | Business Development Director |
| Dr. Walid Abi-Saab M.D. | Chief Medical Officer |
| Mr. Christian Klemt | CFO, Principal Financial Officer & GM of Amsterdam Site |
| Mr. Richard Porter Ph.D. | Chief Business & Scientific Officer |
| Ms. Chiara Elizabeth Russo | Senior Director of Investor Relations |
| Ms. Erin Boyer | Chief People & Culture Officer |
| Ms. Kylie O'Keefe | Chief Customer & Strategy Officer |
| Prof. Hugo Katus | Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany |
| Date | Type | Document |
|---|---|---|
| 2026-05-05 | 10-Q | qure-20260331x10q.htm |
| 2026-04-30 | 8-K | qure-20260430x8k.htm |
| 2026-04-27 | DEFA14A | qure-20260427xdefa14a.htm |
| 2026-04-27 | DEF 14A | qure-20260610xdef14a.htm |
| 2026-04-27 | ARS | qure-20251231xars.pdf |
| 2026-04-16 | PRE 14A | qure-20260610xpre14a.htm |
| 2026-03-02 | 8-K | qure-20260302x8k.htm |
| 2026-03-02 | 10-K | qure-20251231x10k.htm |
| 2026-01-13 | 8-K | qure-20260113x8k.htm |
| 2026-01-09 | 8-K | qure-20260109x8k.htm |